APA (7th ed.) Citation

Fottner, C., Apostolidis, L., Krug, S., Rinke, A., Grün, B., Michl, P., . . . Weber, M. M. (2025). Activity and safety of avelumab in high-grade neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas progressive after chemotherapy (AveNEC trial). Clinical cancer research, 31(5), . https://doi.org/10.1158/1078-0432.CCR-24-2461

Chicago Style (17th ed.) Citation

Fottner, Christian, et al. "Activity and Safety of Avelumab in High-grade Neuroendocrine Tumors and Poorly Differentiated Neuroendocrine Carcinomas Progressive After Chemotherapy (AveNEC Trial)." Clinical Cancer Research 31, no. 5 (2025). https://doi.org/10.1158/1078-0432.CCR-24-2461.

MLA (9th ed.) Citation

Fottner, Christian, et al. "Activity and Safety of Avelumab in High-grade Neuroendocrine Tumors and Poorly Differentiated Neuroendocrine Carcinomas Progressive After Chemotherapy (AveNEC Trial)." Clinical Cancer Research, vol. 31, no. 5, 2025, https://doi.org/10.1158/1078-0432.CCR-24-2461.